Safety, Tolerability, and Efficacy of CP-PCA07 in Combination With Enzalutamide in Patients With Castration-Resistant Prostate Cancer

The purpose of this clinical study is to evaluate the safety, tolerability, and efficacy of CP-PCA07 in combination with enzalutamide in patients with castration-resistant prostate cancer (CRPC). This is an open-label, dose-escalation, multicenter Phase 1 study. The primary objective is to assess the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) to determine the recommended Phase 2 dose (RP2D) of the combination therapy. The secondary objective is to assess changes in Prostate-Specific Antigen (PSA) levels and pharmacokinetic characteristics. Exploratory objectives includ

Trial Details

NCT ID
NCT07683013
Phase
PHASE1
Sponsor
Hyundai Bioscience Co., Ltd.
Status
RECRUITING
Cancer Type
Castration-Resistant (CRPC) Prostate Cancer
Interventions
  • CP-PCA07
  • Enzalutamide 40 mg capsule
Locations (sample)
  • Seoul, South Korea|37.566,126.9784

Key Eligibility Criteria

  • 1\. Male patients aged ≥19 years at the time of providing written informed consent.
  • 2\. Patients with histologically or cytologically confirmed castration-resistant prostate cancer without small-cell features, who have experienced …
  • 3\. Patients with a serum testosterone level \< 50 ng/dL at screening.
  • 4\. Patients with an increase in PSA compared to baseline, confirmed by two consecutive measurements within 8 weeks prior to the date of written in…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Castration-Resistant (CRPC) Prostate Cancer Trials on Trialify →